Mirum Pharmaceuticals
MIRM
80.64
+1.39
+1.75%
Mirum Pharmaceuticals
US · MIRM
#2051 by market cap
Listed 2019
80.64
+1.39
+1.75%
Live - 5344 symbols - heartbeat 377s ago
· 2026-10-08 08:09
Pre-market
80.10
-0.67%
After-hours
80.64
0.00%
- Market cap
- 5.24B
- P/E (TTM)i
- -5.73
- P/Bi
- -500.87
- EPSi
- -0.47
- Div yieldi
- 0.00%
- 52W posi
- 26%
Reader sentiment
Are you bullish or bearish on MIRM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.86, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +54.74% YoY
Margins
- Gross margin
- 80.77%
- Operating margin
- -4.25%
- Net margin
- -4.48%
Key ratios & quality
- Enterprise valuei
- 5.16B
- Altman Z-Scorei
- 5.86
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M |
| Gross profit | -- | -- | 0 | 17.24M | 64.69M | 139.34M | 255.25M | 421.07M |
| Selling & admin expenses | -- | 11.75M | 22.69M | 59.22M | 89.07M | 145.88M | 202.22M | 257.03M |
| Research & development | -- | 42.99M | 81.61M | 131.43M | 106.84M | 102.61M | 140.63M | 186.18M |
| Operating profit | -- | -54.74M | -104.30M | -173.41M | -131.22M | -109.15M | -87.61M | -22.14M |
| Pretax profit | -- | -52.53M | -103.26M | -83.95M | -142.07M | -162.42M | -86.91M | -21.43M |
| Tax | -- | 21.00K | 6.00K | 37.00K | -6.41M | 991.00K | 1.03M | 1.94M |
| Net profit | -- | -52.55M | -103.27M | -83.99M | -135.67M | -163.42M | -87.94M | -23.36M |
| Basic EPS | -- | -5 | -4 | -3 | -4 | -4 | -2 | 0 |
| Diluted EPS | -- | -4.58 | -4.09 | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 111.59M | 127.79M | 133.01M | 148.93M | 159.88M | 176.24M |
| Gross profit | 88.57M | 104.36M | 107.47M | 120.67M | 131.08M | 145.90M |
| Selling & admin expenses | 57.71M | 63.29M | 61.91M | 74.13M | 96.33M | 81.47M |
| Research & development | 41.04M | 46.07M | 42.96M | 51.11M | 97.91M | 90.53M |
| Operating profit | -10.18M | -4.99M | 2.60M | -4.57M | -63.16M | -26.10M |
| Pretax profit | -13.65M | -5.46M | 2.64M | -4.96M | -789.68M | -65.54M |
| Tax | 1.03M | 402.00K | -262.00K | 767.00K | 475.00K | 1.69M |
| Net profit | -14.68M | -5.86M | 2.91M | -5.73M | -790.16M | -67.23M |
| Basic EPS | 0 | 0 | 0 | 0 | -13 | -1 |
| Diluted EPS | -0.30 | -0.12 | 0.05 | -0.11 | -13.43 | -1.06 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 51.98M | 119.36M | 236.35M | 166.59M | 190.23M | 387.54M | 392.79M | 549.68M |
| Cash & ST investments | 51.96M | 116.66M | 231.82M | 156.54M | 151.72M | 286.33M | 280.32M | 383.33M |
| Inventory | -- | -- | 0 | 1.51M | 5.57M | 22.31M | 22.40M | 24.89M |
| Total assets | 51.98M | 146.71M | 240.86M | 294.65M | 352.91M | 646.62M | 670.75M | 842.81M |
| Total current liabilities | 2.45M | 13.08M | 18.46M | 42.60M | 64.73M | 87.06M | 126.55M | 205.80M |
| Short-term debt | -- | 397.00K | 636.00K | 711.00K | 931.00K | 1.10M | 1.71M | 2.14M |
| Long-term debt | -- | -- | -- | -- | -- | 306.42M | 308.08M | 309.80M |
| Total liabilities | 62,298,000.00 | 16,363,000.00 | 68,769,000.00 | 174,439,000.00 | 210,869,000.00 | 397,951,000.00 | 445,114,000.00 | 528,123,000.00 |
| Total equity | -10.32M | 130.35M | 172.10M | 120.21M | 142.04M | 248.67M | 225.64M | 314.69M |
| Retained earnings | -17.35M | -69.90M | -173.17M | -257.16M | -392.82M | -556.24M | -644.18M | -667.54M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 410.82M | 453.40M | 530.58M | 549.68M | 569.44M | 636.31M |
| Cash & ST investments | 277.67M | 304.55M | 375.55M | 383.33M | 386.26M | 438.29M |
| Inventory | 22.42M | 22.94M | 24.02M | 24.89M | 25.52M | 25.77M |
| Total assets | 690.25M | 725.83M | 785.12M | 842.81M | 890.92M | 1.04B |
| Total current liabilities | 127.58M | 144.80M | 160.36M | 205.80M | 272.82M | 222.79M |
| Short-term debt | 1.64M | 2.08M | 2.04M | 2.14M | 2.35M | 2.41M |
| Long-term debt | 308.51M | 308.93M | 309.37M | 309.80M | 310.25M | 750.08M |
| Total liabilities | 456,989,000.00 | 470,667,000.00 | 493,069,000.00 | 528,123,000.00 | 648,422,000.00 | 1,055,403,000.00 |
| Total equity | 233.26M | 255.16M | 292.05M | 314.69M | 242.49M | -10.42M |
| Retained earnings | -658.86M | -664.72M | -661.81M | -667.54M | -1.46B | -1.52B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -39.36M | -89.08M | -132.76M | -120.14M | -70.94M | 10.33M | 55.83M |
| Depreciation & amortization | -- | 324.00K | 623.00K | 595.00K | 3.24M | 10.83M | 23.63M | 24.24M |
| Free cash flow | -- | -39.64M | -89.30M | -151.78M | -120.41M | -91.05M | -10.67M | 54.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 67.20M | 131.87M | 6.91M | 107.37M | 216.68M | 0 | 0 |
| Ending cash balance | -- | 11.97M | 142.09M | 131.34M | 128.00M | 286.33M | 222.93M | 298.17M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -1.96M | 12.04M | 39.68M | 6.07M | -228.76M | -44.25M |
| Depreciation & amortization | 6.05M | 6.06M | 6.06M | 6.07M | 6.87M | 6.94M |
| Free cash flow | -2.00M | 11.91M | 39.49M | 5.47M | -239.43M | -69.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 259.95M | 0 |
| Ending cash balance | 212.25M | 228.60M | 282.50M | 298.17M | 326.64M | 332.46M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -87.57 | -68.29 | -57.47 | -103.46 | -83.65 | -37.08 | -8.65 |
| ROA %i | -- | -52.90 | -53.29 | -31.37 | -41.90 | -32.70 | -13.35 | -3.09 |
| ROIC %i | -- | -87.34 | -67.34 | -47.90 | -92.93 | -46.31 | -15.91 | -3.75 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -80.09 | -69.99 | -58.06 |
| EBIT margin %i | -- | -- | -- | -346.75 | -163.62 | -79.04 | -21.55 | -1.35 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 10.53 |
| Current ratioi | 21.22 | 9.13 | 12.80 | 3.91 | 2.94 | 4.45 | 3.10 | 2.67 |
| Quick ratioi | 21.22 | 8.92 | 12.56 | 3.75 | 2.71 | 4.07 | 2.83 | 2.46 |
| Debt / assetsi | 0.00 | 2.49 | 1.35 | 0.89 | 0.62 | 47.65 | 47.37 | 37.90 |
| LT debt / equityi | -- | 2.49 | 1.53 | 1.58 | 0.89 | 123.47 | 140.07 | 100.83 |
| Interest coveragei | -- | -- | -307.25 | -3.77 | -7.89 | -9.75 | -5.07 | -0.49 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 160.13 | 89.13 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -33.06 | -24.19 | -15.81 | -8.65 | -335.82 | -702.97 |
| ROA %i | -11.52 | -8.45 | -5.70 | -3.09 | -101.04 | -97.15 |
| ROIC %i | -13.99 | -10.23 | -6.89 | -3.75 | -142.93 | -129.73 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -16.24 | -10.02 | -5.61 | -1.35 | -137.47 | -136.57 |
| FCF / sales %i | -- | -- | 9.39 | 10.53 | -- | -- |
| Current ratioi | 3.22 | 3.13 | 3.31 | 2.67 | 2.09 | 2.86 |
| Quick ratioi | 2.93 | 2.84 | 3.01 | 2.46 | 1.90 | 2.62 |
| Debt / assetsi | 45.95 | 43.94 | 40.60 | 37.90 | 36.34 | 73.01 |
| LT debt / equityi | 135.26 | 124.17 | 108.45 | 100.83 | 132.55 | -- |
| Interest coveragei | -4.30 | -3.00 | -1.84 | -0.49 | -54.34 | -62.81 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Livmarli is the largest reported line at 73.04% of revenue, across 2 reported segments.
- The next-largest line, Bile Acid Medicines, is a distant second at 26.96% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Livmarli73.04%
Bile Acid Medicines26.96%
Quote time 2026-10-08 08:09:09 · For reference only, not investment advice and not tailored to your situation.